Ownership and insider activity for Gelteq Limited Ordinary Shares (GELS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Price
| Price | $0.58 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | AU |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-03-18 | WYNNE Paul Michael | |||
| 2026-03-18 | Szewach Simon H | |||
| 2026-07-01 | Szewach Simon H | 65,000 | $130K | |
| 2026-03-18 | Karp Bradley Glenn | |||
| 2026-03-18 | Givoni Nathan J | |||
| 2026-07-01 | Givoni Nathan J | 15,000 | $30K |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $319519 | $181664 | $162485 | $399224 | $24522 | $344648 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $254978 | $193245 | $250666 | $345291 | $183005 | $459724 |
| Inventory | 0 | 0 | $95201 | $95201 | 0 | 0 |
| Total Current Assets | $574497 | $374909 | $720065 | $990974 | $303227 | $1.5M |
| Property, Plant & Equipment | 0 | 0 | $40004 | $10000 | $16642 | $15907 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $44618 | $23.8M | $22.6M | $21.5M | $20.4M | $19.9M |
| Total Assets | $619115 | $24.2M | $23.4M | $22.5M | $20.8M | $21.5M |
| Accounts Payable | $170340 | $85128 | $216725 | $291270 | $387034 | $182632 |
| Short-term Debt | $4595 | $4796 | $5086 | $5086 | $2.1M | $4.2M |
| Total Current Liabilities | $229935 | $235900 | $1.1M | $1.4M | $3.9M | $5.6M |
| Long-term Debt | $166108 | $167328 | $1.5M | $2.5M | $1.8M | $13550 |
| Total Liabilities | $396043 | $403228 | $2.6M | $3.8M | $5.6M | $5.7M |
| Retained Earnings | -$460425 | -$1.1M | -$4.5M | -$7.9M | -$11.5M | -$18.1M |
| Total Equity | $223072 | $23.8M | $20.9M | $18.7M | $15.1M | $15.8M |
| Total Debt | $170703 | $172124 | $1.5M | $2.5M | $3.8M | $4.2M |
| Net Debt | -$148816 | -$9540 | $1.3M | $2.1M | $3.8M | $3.9M |
| Working Capital | $344562 | $139009 | -$360895 | -$373551 | -$3.6M | -$4.1M |
Financial Health
| Debt / Equity | 0.36 |
| Current Ratio | 0.09 |
Profitability
| Return on Equity | -24.94% |
| Return on Invested Capital | -18.33% |
| Return on Assets | -18.59% |
| Gross Margin | 100.00% |
| Operating Margin | -1986.04% |
| Net Margin | -2095.34% |
Related companies: AYTU · BFRG · BFRI · BGLC · COCP · EVGN · IMNN
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of GELS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks